Matthias Christgen

Epigenetic inactivation of microRNA gene <i>hsa‐mir‐9‐1</i> in human breast cancer

Ulrich Lehmann, Britta Hasemeier, Matthias Christgen et al. · The Journal of Pathology · 2007 · 459 citations

Life Sciences, Genetics, Oncology +15

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2016 · 366 citations

Medicine, Oncology, Breast Oncology +16

Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade

Philipp Müller, Matthias Kreuzaler, Tarik A. Khan et al. · Science Translational Medicine · 2015 · 335 citations

Medicine, Oncology, Pharmacology +17

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

Carsten Denkert, Stephan Wienert, Audrey Poterie et al. · Modern Pathology · 2016 · 279 citations · Full text

Life Sciences, Immunology, Oncology +17

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Breast Cancer Research and Treatment · 2017 · 190 citations · Full text

Medicine, Oncology, Breast Oncology +16